+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030

  • ID: 5116506
  • Report
  • March 2020
  • Region: Global
  • 306 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Biocodex
  • DermBiont
  • Karyotica Biologicals
  • Olon
  • Seres Therapeutics
  • MORE

Overview

I believe that a lot of start-ups have entered the market, however, only a few companies have established their own facilities to manufacture microbiome-based products. This is primarily due to the fact that the cost of establishing an LBP production facility is high, and therefore, requires significant capital investment. As a result, companies have demonstrated preference to outsource manufacturing operations

-Vice President, Sales and Business Development, a US based Small-sized Company

Harnessing the naturally evolved, medicinal functions of gut bacteria in order to achieve desired clinical outcomes / benefits is the core principle behind the rapidly growing field of microbiome therapeutics. In fact, in recent years, promising insights from microbiome focused research has been the cause of much enthusiasm within the medical science community, offering a novel perspective related to personalized medicine. This particular class of products exists at the interface of naturopathic remedies (considering the active substances that are currently used) and clinically validated interventions, having demonstrated the ability to offer legitimate, quantifiable clinical benefits. Around 200 companies, including both private and public stakeholders, claim to be currently engaged in developing microbiome-based therapies for the treatment of a wide range of diseases. Several large pharmaceutical companies have also demonstrated interest in partnering with early-stage innovators in this domain. Having said that, most such initiatives are either still in the preclinical stages or early phase clinical trials. There are a few microbiome-based product candidates in phase II/III trials, which are anticipated to drive the market’s growth in the short-mid term. According to our estimates, the microbiome-based therapeutics market is projected to be worth over USD 2.1 billion by 2030, growing at an annualized rate of over 38%.

Despite the evident increase in interest in this field, manufacturing live microbial therapeutics remains a largely unaddressed area of concern. In fact, experts believe that the lack of sufficient manufacturing capacity is one of the major impediments to the commercialization of such products. Other challenges include absence of the required industry standards related to manufacturing live biotherapeutics, reproducibility (batch-to-batch consistency) related concerns, lack of expertise and infrastructure to handle anaerobic microbial strains, scaling up existing manufacturing protocols, intellectual property related issues (existing patent law prohibits patenting live organisms and naturally occurring materials) and uncertainties related to regulatory review and product approval. Owing to the aforementioned reasons and several others, such as need for specialized facilities, equipment and operational expertise, innovator companies have begun relying on contract manufacturers for their microbiome-related development and production needs. Outsourcing is known to offer several benefits, which include reductions in capital investment, access to larger production capacities, expediting time-to-market, and commercial risk handling and mitigation (to a significant extent). Presently, a number of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) claim to offer services for manufacturing microbiome-related products. In fact, some have even developed end-to-end capabilities, starting from drug development to regulatory filings, and commercial scale production, in this field.

Scope of the Report

The “Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030” report features an extensive study of the current landscape and future opportunities related to contract services for microbiome therapeutics. The study features an in-depth analysis, highlighting the capabilities of a diverse set of contract service providers, including CMOs and CDMOs. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics, including information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of  product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic and anaerobic), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company’s contact details.
  • A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise).
  • Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook.
  • An assessment of microbiome contract manufacturing capability in different regions, based on a number of relevant parameters, such as number of CMOs, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of companies offering API / FDF manufacturing, number of companies having capabilities for preclinical / clinical / commercial manufacturing, number of companies dedicated to aerobic / anaerobic fermentation, installed manufacturing capacity, and number of in-house players.
  • A list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account the company’s size and its experience in this field), company’s pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities.
  • A detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials.
  • An estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world).
  • An informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A review of the varied microbiome-focused initiatives of big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity,  and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the microbiome therapeutics contract manufacturing market. Based on multiple parameters, such as projected growth of the overall microbiome therapeutics market, cost of goods sold and direct manufacturing costs, we developed informed estimates describing the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of  product manufactured (API and FDF), [B] type of formulation (solids, oral liquids, injectables and others), [C] company size (small-sized, mid-sized and large), [D] scale of operation (clinical and commercial), and [E] key geographical regions, covering North America, Europe, Asia-Pacific, and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study was influenced by inputs solicited via a survey and discussions held with multiple senior stakeholders in the industry.

The report features detailed transcripts of discussions held with the following individuals:

  • Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
  • Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)
  • Assaf Oron (Chief Business Officer, BiomX)
  • Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)
  • Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
  • JP Benya (Vice President, Business Development, Assembly Biosciences)
  • Rob van Dijk (Business Development Manager, Wacker Biotech)
  • Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading CMOs offering microbiome contract manufacturing services, across the world?
  • What are the key challenges faced by microbiome contract manufacturers?
  • Who are the most likely partners (microbiome-based live biotherapeutic drug developers) for microbiome contract manufacturers?
  • What is the annual clinical demand for microbiome-based live biotherapeutic products?
  • What is the current, installed contract manufacturing capacity for live biotherapeutics?
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision in this field?
  • What are the various initiatives undertaken by big pharma players in this domain?
  • What percentage of live biotherapeutics manufacturing operations are outsourced to service providers?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to live biotherapeutics manufacturing?
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Biocodex
  • DermBiont
  • Karyotica Biologicals
  • Olon
  • Seres Therapeutics
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Human Microbiota and Microbiome
3.3. Overview of Gut Flora
3.2.3. Role of Gut Flora in Healthy Individuals
3.2.4. Factors Affecting Human Gut Flora
3.4. The Human Microbiome Project (HMP)
3.5. Overview of Microbiome Therapies
3.5.1. Types of Microbiome Therapies
3.5.1.1. Probiotics
3.5.1.2. Prebiotics
3.5.2. Applications of Microbiome Therapies
3.5.3. Microbiome Therapies Supply Chain
3.6. Microbiome-based Product Manufacturing
3.6.1. Key Steps Involved
3.6.2. Associated Challenges
3.6.3. Role of Contract Manufacturing Organizations (CMOs)
3.6.4. Demand for Contract Manufacturing Services
3.7. Key Considerations for Selecting a Suitable CMO Partner

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CMOs Offering Contract Manufacturing for Microbiome Therapeutics: List of Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Type of Service Offered
4.2.6. Analysis by Type of Product Manufactured
4.2.7. Analysis by Type of Drug Molecule
4.2.8. Analysis by Type of Fermentation Required
4.2.9. Analysis by Type of Formulation
4.2.10. Analysis by Type of Primary Packaging Used
4.2.11. Analysis by Number of Manufacturing Facilities
4.2.12. Analysis by Location of Manufacturing Facilities
4.2.13. Analysis by Type of Regulatory Certifications / Accreditations
4.3. Microbiome Therapeutics In-House Manufacturers: List of Companies
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Scale of Operation
4.3.4. Analysis by Location of Headquarters
4.3.5. Analysis by Location of Manufacturing Facilities

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. CMOs Headquartered in North America
5.2.1. Capsugel
5.2.1.1. Company Overview
5.2.1.2. Microbiome-Related Service Portfolio
5.2.1.3. Facilities Dedicated to Microbiome Manufacturing
5.2.1.4. Recent Developments and Future Outlook
5.2.2. Paragon Bioservices
5.2.2.1. Company Overview
5.2.2.2. Microbiome-Related Service Portfolio
5.2.2.3. Facilities Dedicated to Microbiome Manufacturing
5.2.2.4. Recent Developments and Future Outlook
5.2.3. UAS Labs
5.2.3.1. Company Overview
5.2.3.2. Microbiome-Related Service Portfolio
5.2.3.3. Facilities Dedicated to Microbiome Manufacturing
5.2.3.4. Recent Developments and Future Outlook
5.3. CMOs Headquartered in Europe
5.3.1. Biose
5.3.1.1. Company Overview
5.3.1.2. Microbiome-Related Service Portfolio
5.3.1.3. Facilities Dedicated to Microbiome Manufacturing
5.3.1.4. Recent Developments and Future Outlook
5.3.2. Cobra Biologics
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Microbiome-Related Service Portfolio
5.3.2.4. Facilities Dedicated to Microbiome Manufacturing
5.3.2.5. Recent Developments and Future Outlook
5.3.3. Cerbios
5.3.3.1. Company Overview
5.3.3.2. Microbiome-Related Service Portfolio
5.3.3.3. Facilities Dedicated to Microbiome Manufacturing
5.3.3.4. Recent Developments and Future Outlook
5.3.4. Inpac Probiotics
5.3.4.1. Company Overview
5.3.4.2. Microbiome-Related Service Portfolio
5.3.4.3. Facilities Dedicated to Microbiome Manufacturing
5.4. CMOs Headquartered in Asia-Pacific and Rest of the World
5.4.1. BJP Laboratories
5.4.1.1. Company Overview
5.4.1.2. Microbiome-Related Service Portfolio
5.4.1.3. Facilities Dedicated to Microbiome Manufacturing

6. REGIONAL CAPABILITY ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Regional Capability Analysis: Microbiome Contract Manufacturers in North America
6.4. Regional Capability Analysis: Microbiome Contract Manufacturers in Europe
6.5. Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World
6.6. Concluding Remarks

7. LIKELY PARTNER ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Potential Strategic Partners for Microbiome Contract Manufacturers
7.3.1. Opportunities in North America
7.3.2. Opportunities in Europe and Asia-Pacific

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Clinical Trial Analysis (Industry Players)
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Phase
8.3.3. Analysis by Trial Recruitment Status
8.3.4. Analysis by Trial Registration Year and Recruitment Status
8.3.5. Analysis by Trial Registration Year and Number of Patients Enrolled
8.3.6. Analysis by Study Design
8.3.7. Analysis by Trial Focus
8.3.8. Analysis by Trial Phase and Type of Intervention Model
8.3.9. Analysis by Sponsor / Collaborator
8.3.10. Analysis by Type of Organization
8.3.11. Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year
8.3.12. Geographical Analysis by Number of Clinical Trials
8.3.13. Geographical Analysis by Trial Recruitment Status
8.4. Clinical Trial Analysis (Non-Industry Players)
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Phase
8.4.3. Analysis by Trial Recruitment Status
8.4.4. Analysis by Trial Registration Year and Recruitment Status
8.4.5. Analysis by Trial Registration Year and Number of Patients Enrolled
8.4.6. Analysis by Study Design
8.4.7. Analysis by Trial Focus
8.4.8. Analysis by Trial Phase and Type of Intervention Model
8.4.9. Analysis by Sponsor / Collaborator
8.4.10. Analysis by Type of Organization
8.4.11. Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year
8.4.12. Geographical Analysis by Number of Clinical Trials
8.4.13. Geographical Analysis by Trial Recruitment Status

9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Microbiome Contract Manufacturers: Global Production Capacity
9.3.1. Analysis by Company Size
9.3.1.1. Overall Production Capacity of Small-sized Companies
9.3.1.2. Overall Production Capacity of Mid-sized Companies
9.3.1.3. Overall Production Capacity of Large Companies
9.3.2. Analysis by Scale of Operation
9.3.2.1. Overall Clinical Scale Production Capacity
9.3.2.2. Overall Commercial Scale Production Capacity
9.3.3. Analysis by Location of Manufacturing Facility
9.3.3.1. Overall Production Capacity in North America
9.3.3.2. Overall Production Capacity in Europe
9.3.3.3. Overall Production Capacity in Asia-Pacific and Rest of the World
9.4. Concluding Remarks

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Global Clinical Demand for Microbiome Contract Manufacturing
10.3.1. Geographical Analysis of Demand
10.3.1.1. Clinical Demand in North America
10.3.1.2. Clinical Demand in Europe
10.3.1.3. Clinical Demand in Asia-Pacific and Rest of the World
10.3.2. Phase-Wise Analysis of Demand
10.3.2.1. Clinical Demand in Phase I
10.3.2.2. Clinical Demand in Phase II
10.3.2.3. Clinical Demand in Phase III
10.3.3. Sponsor Wise Analysis of Demand
10.3.2.1. Clinical Demand for Industry Sponsors
10.3.2.2. Clinical Demand for Non-Industry Sponsors
10.4 Concluding Remarks

11. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
11.1. Chapter Overview
11.2. Make versus Buy Decision Making: Assumptions and Parameter Definitions
11.2.1. Scenario 1: High Value Addition / Low Complexity
11.2.1. Scenario 2: High Value Addition / High Complexity
11.2.1. Scenario 3: Low Value Addition / Low Complexity
11.2.1. Scenario 4: Low Value Addition / High Complexity
11.3. Contract Manufacturer’s Perspective
11.4. Concluding Remarks

12. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Initiatives of Big Pharmaceutical Players
12.3.1. Analysis by Portfolio Diversity
12.3.2. Analysis by Phase of Development
12.3.3. Analysis by Type of Therapeutic
12.3.4. Analysis by Type of Drug Molecule
12.3.5. Heat Map: Analysis by Target Therapeutic Areas
12.4. Benchmark Analysis of Big Pharmaceutical Players
12.4.1. Spider Web Analysis: Company A
12.4.2. Spider Web Analysis: Company B
12.4.3. Spider Web Analysis: Company C
12.4.4. Spider Web Analysis: Company D
12.4.5. Spider Web Analysis: Company E
12.4.6. Spider Web Analysis: Company F
12.4.7. Spider Web Analysis: Company G
12.4.8. Spider Web Analysis: Company H
12.4.9. Spider Web Analysis: Company I
12.4.10. Spider Web Analysis: Company J
12.4.11. Spider Web Analysis: Company K
12.5. Concluding Remarks

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Microbiome Contract Manufacturing Market, 2020-2030
13.4 Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Product Manufactured
13.4.1. Microbiome Contract Manufacturing Market for APIs, 2020-2030
13.4.2. Microbiome Contract Manufacturing Market for FDFs, 2020-2030
13.5. Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Type of Formulation
13.5.1. Microbiome Contract Manufacturing Market for Solid Formulations, 2020-2030
13.5.2. Microbiome Contract Manufacturing Market for Oral Liquids, 2020-2030
13.5.3. Microbiome Contract Manufacturing Market for Injectables, 2020-2030
13.5.4. Microbiome Contract Manufacturing Market for Others, 2020-2030
13.6. Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.6.1. Microbiome Contract Manufacturing Market for Clinical Scale Operations, 2020-2030
13.6.2. Microbiome Contract Manufacturing Market for Commercial Scale Operations, 2020-2030
13.7. Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Company Size
13.7.1. Microbiome Contract Manufacturing Market for Small-sized Companies, 2020-2030
13.7.2. Microbiome Contract Manufacturing Market for Mid-sized Companies, 2020-2030
13.7.3. Microbiome Contract Manufacturing Market for Large Companies, 2020-2030
13.8. Microbiome Contract Manufacturing Market, 2020-2030: Geographical Distribution
13.8.1. Microbiome Contract Manufacturing Market in North America, 2020-2030
13.8.2. Microbiome Contract Manufacturing Market in Europe, 2020-2030
13.8.3. Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2020-2030
13.9. Concluding Remarks

14. CONCLUSION
14.1. Chapter Overview
14.2. Key Takeaways

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. S-Biomedic
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer
15.3. Meteoric Biopharmaceuticals
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Gaurav Kaushik, Managing Director and Chief Executive Officer
15.4. BiomX
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Assaf Oron, Chief Business Officer
15.5. Universal Stabilization Technologies
15.5.1 Company Snapshot
15.5.2. Interview Transcript: Alexander Segal, Vice President, Business Development
15.6. List Biological Laboratories
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development
15.7. Assembly Biosciences
15.7.1. Company Snapshot
15.7.2. Interview Transcript: JP Benya, Vice President, Business Development
15.8. Wacker Biotech
15.8.1 Company Snapshot
15.8.2. Interview Transcript: Rob van Dijk, Business Development Manager
15.9. Chung Mei Pharmaceutical
15.9.1. Company Snapshot
15.9.2. Interview Transcript: Alexander Lin, Associate General Manager

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Note: Product cover images may vary from those shown
3 of 4
  • 3P Biopharmaceuticals
  • 3SBio
  • 4D Pharma
  • 53Biologics
  • AbbVie
  • AbbVie Contract Manufacturing
  • ABCO Laboratories
  • ABH Pharma
  • AceBiome
  • ActoBio Therapeutics (a subsidiary of Intrexon)
  • Actygea
  • Adare Pharmaceuticals
  • ADM Biopolis
  • ADM Protexin
  • Advanced BioScience Laboratories
  • Advanced Enzymes
  • Affinity Life Sciences
  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • Albumedix
  • Aldevron
  • Allergan
  • Allianz Biosciences
  • AMAbiotics
  • AMRI
  • AOBiome Therapeutics
  • APC Microbiome Institute
  • Armata Pharmaceuticals
  • Arranta Bio
  • Assembly Biosciences
  • AST Enzymes
  • AstraZeneca
  • Atlantic Essential Products
  • Aumgene Biosciences
  • AURA Biotechnologies
  • Axcellerate Pharma
  • Axial Biotherapeutics
  • Azitra
  • BacThera
  • Batavia Biosciences
  • Baylor College of Medicine
  • Biena
  • Bifodan
  • Binex
  • Bio Elpida
  • Bio Farma
  • Bio Synergy
  • BioCare Copenhagen
  • BioCell
  • Biocodex
  • BIOFABRI
  • BioGaia
  • Bio-K Plus International
  • Biological E.
  • BioMARC
  • Biomica (a subsidiary of Evogene)
  • BiomX
  • BioProduction by Sekisui
  • biose
  • Biosortia Pharmaceuticals
  • Bio-Synthesis
  • Bio-Technology General
  • BioThrive Sciences
  • BioVectra
  • Biovian
  • BJP Laboratories
  • Bloom Science
  • Blue Turtle Bio Technologies
  • Boehringer Ingelheim BioXcellence
  • Boston Analytical
  • Boston Institute of Biotechnology
  • Boston Medical Center
  • Bristol-Myers Squibb
  • Broad Institute
  • Caelus Health
  • Capsugel
  • Capua BioServices
  • Carbiotix
  • Catalent Biologics
  • Cell Biotech
  • Cerbios-Pharma
  • CEVEC Pharmaceuticals
  • CHAIN Biotechnology
  • Charles River Laboratories
  • ChemPartner Biologics
  • CinnaGen
  • ClostraBio
  • Cobra Biologics
  • Commense (a subsidiary of PureTech Health)
  • Concord Biotech
  • Corden BioChem
  • Creative Biolabs
  • Crown Laboratories
  • Custom Probiotics
  • Cytovance Biologics
  • DANIN International
  • DaVolterra
  • DayTwo
  • Deerland Probiotics & Enzymes
  • DermBiont
  • DuPont
  • EirGenix
  • EKF Life Sciences
  • Elmed
  • Emerge Nutraceuticals
  • Emergent Biosolutions
  • EMF
  • Enteris BioPharma
  • Enterome
  • Etinpro
  • EuBiologics
  • EUCODIS Bioscience
  • Eurogentec
  • Evelo Biosciences
  • Evogene
  • Evonik Health Care
  • EXDEN
  • Exeliom Biosciences
  • Exim Pharma
  • Ferring Pharmaceuticals
  • Finch Therapeutics
  • Food and Agriculture Organization
  • FUJIFILM Diosynth Biotechnologies
  • Ganeden
  • GE Healthcare
  • GenIbet Biopharmaceuticals
  • GENIBIO (a subsidiary of the LARENA and GB ACTION)
  • Genome and Company
  • GI Innovation
  • GSK Contract Manufacturing
  • GTP Technology
  • Gusto Global
  • Holobiome
  • Hong Kong Institute of Biotechnology
  • Igen Biotech
  • ImmuneBiotech
  • Immuron
  • Infact Bacterial Therapeutics
  • Inpac Probiotics
  • Institute for Research in Biomedicine (IRB)
  • Intron Life Sciences (ILS)
  • Ion Labs
  • IVERIC bio
  • J. Craig Venter Institute
  • Jeneil Biotech
  • JLABS
  • Johnson & Johnson
  • JW Nutritional
  • Kaleido Biosciences
  • Kallyope
  • Kanda Biotech
  • Karyotica Biologicals
  • KBI Biopharma
  • Kendy Pharma
  • Kibow Biotech
  • KNect365 Life Sciences
  • LakePharma
  • Lallemand
  • Leadiant Biosciences
  • List Biological Laboratories
  • LNC Therapeutics
  • Locus Biosciences
  • Lonza
  • LUCA Biologics
  • Luina Bio
  • Mabion Poland
  • Maine Biotechnology Services
  • MatriSys Bioscience
  • Medella Naturals
  • Medella Springs Healthcare
  • Menarini Biotech
  • Merck
  • Merck Millipore
  • MeriCal
  • Meridian Life Science
  • MetaboGen
  • Meteoric Biopharmaceuticals
  • Microbax
  • MicroBiopharm Japan
  • Microbiotica
  • Mologic
  • MyBiotics
  • Mycenax Biotech
  • Naked Biome
  • National Cancer Institute (NCI)
  • National Enzyme Company (NEC)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institutes of Health Clinical Center
  • NDB Healthcare
  • Nebraska Cultures
  • New Bellus
  • NIZO
  • Norax Supplements
  • Northway BiotechPharma
  • Novartis
  • Novavax
  • Novo Nordisk
  • NOW Foods
  • NuBiyota
  • NUMAFERM
  • NutraScience Labs
  • Ology Bioservices
  • Olon
  • Orkila
  • Osel
  • OxThera
  • Panacea Biotec
  • Paragon Bioservices (unit of Catalent Biologics)
  • Paras Biopharmaceuticals Finland
  • Pfizer
  • Pfizer CentreOne
  • Pharma-Zentrale
  • Phi Therapeutics
  • Pierre Fabre
  • PiLeJe
  • Polpharma Biologics
  • Polymun Scientific
  • Porton Biopharma
  • Premas Biotech
  • Probi
  • ProbioFerm
  • Probiotic Holdings
  • Probiotical
  • Probiotics Australia
  • Probiotics International
  • Probium
  • Proventus Bioscience
  • Pure Cultures
  • PX’Therapeutics
  • Qu Biologics
  • Quay Pharma
  • Quest Nutra Pharma
  • Quorum Innovations
  • Rebiotix (a subsidiary of Ferring Pharmaceuticals)
  • Retron Probiotics
  • Richter-Helm BioLogics
  • Rise Therapeutics
  • Ritter Pharmaceuticals
  • Roche
  • Sabinsa Europe (a subsidiary of Sami Labs)
  • Sacco
  • Sandoz
  • Sarepta Therapeutics
  • S-Biomedic
  • SciBac
  • Scientific Protein Laboratories
  • Scil Proteins Pharma
  • Scioto Biosciences
  • Second Genome
  • Seed Health
  • Seres Therapeutics
  • SFA Therapeutics
  • SGL Probiotics
  • Siam Bioscience
  • SiliCycle
  • Siolta Therapeutics
  • Sirio Pharma
  • SkinBioTherapeutics
  • Snipr Biome
  • Specialty Enzymes & Probiotics
  • Stelis BioSource™
  • Symberix
  • Symbiotix Biotherapies
  • Syngen Biotech
  • Syngene Interntional
  • Synlogic (acquired by Mirna Therapeutics)
  • Synthetic Biologics
  • Takeda Pharmaceutical
  • TargEDys
  • TARON Solutions
  • Teva Pharmaceutical
  • The Native Antigen
  • Therapure BioPharma
  • Thermo Fisher Scientific
  • THT: probiotics and starter cultures
  • Tokyo Chemical Industry
  • Touchlight Genetics
  • Trayer Biotherapeutics
  • TRU-ID
  • UAS Labs
  • Unique Biotech
  • University of California
  • University of Liverpool
  • University of Oxford
  • University of Pennsylvania
  • University of Pittsburgh
  • Vaiomer
  • Vedanta Biosciences (a subsidiary of PureTech Health)
  • VGXI
  • Virun Nutra-Biosciences
  • VITA-gen Laboratories
  • Vitakem
  • ViThera Pharmaceuticals
  • VxP Biologics
  • WACKER Biotech
  • Waisman Biomanufacturing
  • Washington University School of Medicine
  • Weizmann Institute of Science
  • Winclove Probiotics
  • World Health Organization (WHO)
  • WuXi Biologics
  • Xycrobe Therapeutics (a subsidiary of Crown Laboratories)
  • Yakult Honsha
  • Zeta Farmaceutici
  • Zhejiang Hisun Pharmaceutical
  • Zytex
Note: Product cover images may vary from those shown
4 of 4

 

 

Loading
LOADING...

Adroll
adroll